Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP5C | P53041 | 2/20 | 0.39 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.39 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16731268 | 0.82 | PPP5C (0.41) | PPP5CPPP2CATFPI2NPY4RTSHR | |
| SCHEMBL26377824 | 0.81 | TFPI2 (0.59) | PPP5CPPP2CATFPI2NPY4RTSHR | |
| SCHEMBL11885821 | 0.81 | TFPI2 (0.59) | PPP5CPPP2CATFPI2NPY4RTSHR | |
| SCHEMBL9880170 | 0.81 | TFPI2 (0.59) | PPP5CPPP2CATFPI2NPY4RTSHR | |
| SCHEMBL9880160 | 0.80 | TSHR (0.54) | PPP5CPPP2CATFPI2NPY4RTSHR | |
| SCHEMBL16731269 | 0.79 | PPARG (0.39) | PPP5CPPP2CATFPI2NPY4RTSHR | |
| SCHEMBL16731415 | 0.79 | PPARG (0.39) | PPP5CPPP2CATFPI2NPY4RTSHR | |
| SCHEMBL9880146 | 0.76 | TFPI2 (0.60) | PPP5CPPP2CATFPI2NPY4RTSHR | |
| SCHEMBL9880162 | 0.74 | PPP5C (0.48) | PPP5CPPP2CATFPI2NPY4RTSHR | |
| SCHEMBL9881386 | 0.73 | PPP5C (0.49) | PPP5CPPP2CATFPI2NPY4RTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275521-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | LIXTE BIOTECHNOLOGY, INC. | 2021-09-09 | — | — | US | disclosed |
| EP-3258930-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | LIXTE BIOTECHNOLOGY INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-10668062-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | LIXTE BIOTECHNOLOGY, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10434100-B2 | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10413541-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2019113155-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190167671-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | LIXTE BIOTECHNOLOGY, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190046525-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-02-14 | — | — | US | disclosed |
| EP-2870161-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF REPERFUSION INJURY | LIXTE BIOTECHNOLOGY INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2714924-B1 | HDAC Inhibitors for use in the treatment of Gaucher's disease, von Hippel-Lindau disease, phaeochromocytoma and paragangliomas. | LIXTE BIOTECHNOLOGY INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-8541458-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2012162535-A1 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | LIXTE BIOTECHNOLOGY, INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | LIXTE BIOTECHNOLOGY, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8227473-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227473-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120135522-A1 | METHODS OF MODULATING CELL REGULATION BY INHIBITING P53 | LIXTE BIOTECHNOLOGY, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120135522-A1 | METHODS OF MODULATING CELL REGULATION BY INHIBITING P53 | LIXTE BIOTECHNOLOGY, INC. | 2012-05-31 | — | — | US | disclosed |
| WO-2010014254-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10413541-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | HSD17B11, HSD17B1, CRH | PPP5C 2219/4885PPP2CA 472/4885TFPI2 4289/4885 |
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | PPP5C 3037/4885PPP2CA 2107/4885TFPI2 4858/4885 |
| US-20190167671-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | PPP2CA, PPP3CA, PPP6C | PPP5C 12/4885PPP2CA 1/4885TFPI2 3732/4885 |
| US-20190046525-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | PPP2CA, PPP2R2A, PPM1A | PPP5C 8/4885PPP2CA 1/4885TFPI2 1195/4885 |
| US-20210275521-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | MCL1, MYD88, SAMHD1 | PPP5C 1464/4885PPP2CA 688/4885TFPI2 4378/4885 |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | HCCS, OXA1L, OTC | PPP5C 3037/4885PPP2CA 2107/4885TFPI2 4858/4885 |
| US-10434100-B2 | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes | PPP2CA, PPP2R2A, PPM1A | PPP5C 8/4885PPP2CA 1/4885TFPI2 1195/4885 |
| US-10668062-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | PPP2CA, PPP3CA, PPP6C | PPP5C 12/4885PPP2CA 1/4885TFPI2 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.